Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
Masahiko Mihara1, Yoshiyuki Ohsugi2, Tadamitsu Kishimoto31Product Research Department, Chugai Pharmaceutical Co Ltd, Fuji-Gotemba Research Laboratories, Shizuoka, Japan; 2Chugai Pharmaceutical Co Ltd, Tokyo, Japan; 3Laboratory of Immunoregulation, Graduate School of Frontier Biosciences, Osaka Unive...
Main Authors: | Masahiko Mihara, Yoshiyuki Ohsugi, Tadamitsu Kishimoto |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-02-01
|
Series: | Open Access Rheumatology : Research and Reviews |
Online Access: | http://www.dovepress.com/tocilizumab-a-humanized-anti-interleukin-6-receptor-antibody-for-treat-a6493 |
Similar Items
-
Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis
by: Elinoar Hoffman, et al.
Published: (2019-09-01) -
Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody
by: Mitsuaki Yanagida, et al.
Published: (2013-01-01) -
New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)
by: Evgeniy L'vovich Nasonov, et al.
Published: (2010-05-01) -
Increase of hemoglobin levels by anti-IL-6 receptor antibody (tocilizumab) in rheumatoid arthritis.
by: Motomu Hashimoto, et al.
Published: (2014-01-01) -
Anti-IL-6 Receptor Antibody Causes Less Promotion of Tuberculosis Infection than Anti-TNF-𝛼 Antibody in Mice
by: Masaji Okada, et al.
Published: (2011-01-01)